Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales
Sarepta’s stock dropped by 26% after the FDA named a vocal critic of its gene therapy programme to lead its biologics division.
Sarepta’s stock dropped by 26% after the FDA named a vocal critic of its gene therapy programme to lead its biologics division.
What's Your Reaction?
